Menu Close

Trending

Omnichannel strategies to revolutionize the healthcare professional experience
Partners come on board GSK’s plan for Stevenage life science hub
UK adds £175m funding to clinical research recovery drive
StartUp Health takes a multidisciplinary approach to fight type 1 diabetes
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

siRNA

heart-840x470

News/ News/ R&D

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

, , , , , , , , , 0 Comment

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible

X
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
https://pharmaphorum.com/news/amgen-eyes-swift-move-to-ph3-for-cardiovascular-drug-olpasiran/
AZ adds gene silencing tech to pipeline with Silence Therapeutics deal

News/ News/ R&D

AZ adds gene silencing tech to pipeline with Silence Therapeutics deal

, , , , , 0 Comment

AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal,

X
AZ adds gene silencing tech to pipeline with Silence Therapeutics deal
https://pharmaphorum.com/news/az-adds-gene-silencing-tech-to-pipeline-with-silence-therapeutics-deal/

Login

CONTINUE TO SITE >
X
Close in 10 seconds